Bolt Biotherapeutics, Inc. - Common Stock (NQ:BOLT)

6.270 +2.080 (+49.64%)

Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bolt Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BOLT

July 08, 2024

From The Rosen Law Firm PA

Via GlobeNewswire

Bolt Biotherapeutics, Inc. Stockholder Notice: Robbins LLP Reminds Investors of the BOLT Class Action

July 08, 2024

From Robbins LLP

Via Business Wire

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BOLT

July 05, 2024

From The Rosen Law Firm PA

Via GlobeNewswire

Shareholder Alert: Robbins LLP Informs Stockholders of the Class Action Filed Against Bolt Biotherapeutics, Inc. (BOLT)

July 03, 2024

From Robbins LLP

Via GlobeNewswire

BOLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Bolt Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

July 03, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

ROSEN, A TOP RANKED LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BOLT

July 03, 2024

From The Rosen Law Firm, P.A.

Via Business Wire

The Analyst Anxiety Index: 3 Stocks to Avoid as Uncertainty Grows ↗

May 24, 2024

Explore key stocks with analyst uncertainty to avoid amid contrasting global market highs and risky downgrades.

Via InvestorPlace

Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

May 15, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

May 15, 2024

Via Benzinga

This Accenture Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Today ↗

May 15, 2024

Via Benzinga

Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket ↗

May 15, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

May 15, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

May 15, 2024

We are covering the biggest pre-market stock movers for Wednesday with all of the latest happenings worth watching this morning!

Via InvestorPlace

BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q1 2024 ↗

May 14, 2024

BOLT stock results show that Bolt Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

May 14, 2024

Via Benzinga

Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team

May 14, 2024

From Bolt Biotherapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

April 03, 2024

Via Benzinga

BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q4 2023 ↗

March 21, 2024

BOLT stock results show that Bolt Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.

Via InvestorPlace

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

March 21, 2024

From Bolt Biotherapeutics, Inc.

Via GlobeNewswire

Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference

February 27, 2024

From Bolt Biotherapeutics, Inc.

Via GlobeNewswire

Pacira Appoints Frank D. Lee as Chief Executive Officer

December 21, 2023

From Pacira BioSciences

Via GlobeNewswire

Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®

December 05, 2023

From Bolt Biotherapeutics, Inc.

Via GlobeNewswire

Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

November 09, 2023

From Bolt Biotherapeutics, Inc.

Via GlobeNewswire

Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference

November 07, 2023

From Bolt Biotherapeutics, Inc.

Via GlobeNewswire

10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis

October 23, 2023

Via ACCESSWIRE

Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress

October 23, 2023

From Bolt Biotherapeutics, Inc.

Via GlobeNewswire

Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting

October 18, 2023

From Bolt Biotherapeutics, Inc.

Via GlobeNewswire

Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers

October 17, 2023

From Bolt Biotherapeutics, Inc.

Via GlobeNewswire

Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023

October 16, 2023

From Bolt Biotherapeutics, Inc.

Via GlobeNewswire

Why AERWINS Technologies Shares Are Trading Higher By Around 90%; Here Are 20 Stocks Moving Premarket ↗

October 02, 2023

Gainers AERWINS Technologies Inc. (NASDAQ: AWIN) shares rose 90.2% to $0.2297 in pre-market trading. Aerwins Technologies is considering strategic alternatives for non-core operations including, not...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.